Edition:
India

Lupin Ltd (LUPN.NS)

LUPN.NS on National Stock Exchange of India

734.90INR
23 May 2018
Change (% chg)

Rs-5.20 (-0.70%)
Prev Close
Rs740.10
Open
Rs745.20
Day's High
Rs749.90
Day's Low
Rs733.10
Volume
744,439
Avg. Vol
1,577,552
52-wk High
Rs1,274.95
52-wk Low
Rs723.65

Latest Key Developments (Source: Significant Developments)

Lupin Submits Marketing Authorization Application For Etanercept Biosimilar In Europe
Friday, 25 May 2018 

May 25 (Reuters) - Lupin Ltd ::SAYS CO SUBMITS MARKETING AUTHORIZATION APPLICATION FOR ETANERCEPT BIOSIMILAR IN EUROPE.SAYS MARKETING AUTHORIZATION APPLICATION FOR ETANERCEPT BIOSIMILAR ACCEPTED FOR REVIEW BY EUROPEAN MEDICINES AGENCY.SAYS CO ON COURSE WITH ITS PLANS FOR BIOSIMILAR ETANERCEPT FILING IN U.S. AND IS TARGETING THE SAME IN FY 2019-20.  Full Article

Lupin Says US FDA Inspection Concluded At Co's Nagpur Facility With No Observations
Monday, 14 May 2018 

May 14 (Reuters) - Lupin Ltd ::SAYS CO'S NAGPUR FACILITY'S US FDA INSPECTION CONCLUDED WITH NO OBSERVATIONS.  Full Article

Lupin Launches Corcal Bone And Beauty Supplement
Thursday, 10 May 2018 

May 10 (Reuters) - Lupin Ltd ::LAUNCHES CORCAL BONE AND BEAUTY SUPPLEMENT.  Full Article

Lupin Submits New Drug Application For Etanercept Biosimilar In Japan
Tuesday, 8 May 2018 

May 8 (Reuters) - Lupin Ltd ::SAYS SUBMITS NEW DRUG APPLICATION FOR ETANERCEPT BIOSIMILAR IN JAPAN.SAYS APPLICATION FOR A DRUG TO TREAT INDICATIONS FOR MODERATE TO SEVERE RHEUMATOID ARTHRITIS, JUVENILE IDIOPATHIC ARTHRITIS.IS ALSO ON COURSE WITH PLANS FOR FILING IN U.S.; TARGETING A FILING IN FY 2019-20.  Full Article

India's Lupin Gets FDA Nod For Generic Xenazine Tablets, 12.5 Mg And 25 Mg
Monday, 23 Apr 2018 

April 23 (Reuters) - Lupin Ltd ::SAYS CO RECEIVES FDA APPROVAL FOR GENERIC XENAZINE TABLETS, 12.5 MG AND 25 MG.  Full Article

India's Lupin Gets Tentative U.S. FDA Nod For Generic Androgel, 1.62 Pct
Tuesday, 17 Apr 2018 

April 17 (Reuters) - Lupin Ltd ::SAYS CO RECEIVES TENTATIVE FDA APPROVAL FOR GENERIC ANDROGEL, 1.62 PERCENT.  Full Article

Lupin's Pithampur Unit 1 Facility Gets EIR From U.S. FDA
Friday, 6 Apr 2018 

April 6 (Reuters) - Lupin Ltd ::SAYS PITHAMPUR UNIT 1 FACILITY RECEIVES ESTABLISHMENT INVESTIGATION REPORT (EIR) FROM US FDA.SAYS THE INSPECTION WAS CONDUCTED IN JULY 2017.  Full Article

India's Lupin ‍​Gets FDA Nod For Generic Clobexa Spray, 0.05 Pct
Tuesday, 27 Mar 2018 

March 27 (Reuters) - Lupin Ltd ::SAYS CO ‍​GETS FDA APPROVAL FOR GENERIC CLOBEXA SPRAY, 0.05%.  Full Article

Lupin Launches Generic Lodosyn Tablets In The U.S.
Monday, 26 Mar 2018 

March 26 (Reuters) - Lupin Ltd ::SAYS LUPIN LAUNCHES GENERIC LODOSYN TABLETS IN THE US.  Full Article

Lupin Launches Tydem Tablets
Tuesday, 13 Mar 2018 

March 13 (Reuters) - Lupin Ltd ::SAYS LAUNCH OF TYDEM TABLETS.  Full Article

Photo

Lupin expects U.S. drug pricing pressure to ease in 2019

India's second-largest drugmaker Lupin Ltd said on Wednesday it expected pressure on drug prices in the United States, which has hit its profits, to ease this year as larger rivals reduce their exposure there.